Sökning: onr:"swepub:oai:gup.ub.gu.se/325085" >
Dual or single anti...
Dual or single antiplatelet therapy after coronary surgery for acute coronary syndrome (TACSI trial): Rationale and design of an investigator-initiated, prospective, multinational, registry-based randomized clinical trial
-
- Malm, Carl Johan (författare)
- University of Gothenburg,Gothenburg University,Göteborgs universitet,Institutionen för medicin, avdelningen för molekylär och klinisk medicin,Institute of Medicine, Department of Molecular and Clinical Medicine,Sahlgrenska Academy,Sahlgrenska University Hospital
-
- Alfredsson, Joakim (författare)
- Linköping University,Linköpings universitet,Avdelningen för diagnostik och specialistmedicin,Medicinska fakulteten,Region Östergötland, Kardiologiska kliniken US,Linköping University Hospital
-
- Erlinge, David (författare)
- Lund University,Lunds universitet,Molekylär kardiologi,Forskargrupper vid Lunds universitet,Molecular Cardiology,Lund University Research Groups
-
visa fler...
-
- Gudbjartsson, T. (författare)
- Landspitali Univ Hosp, Iceland; Univ Iceland, Iceland,National University Hospital of Iceland
-
- Gunn, J. (författare)
- Turku Univ Hosp, Finland; Univ Turku, Finland,University of Turku,Turku University Hospital
-
- James, S. (författare)
- University of Gothenburg,Uppsala University,Sahlgrenska Academy,Sahlgrenska University Hospital
-
- Moller, C. H. (författare)
- Copenhagen Univ Hosp, Denmark; Univ Copenhagen, Denmark,University of Copenhagen,Copenhagen University Hospital
-
- Nielsen, Susanne, 1969 (författare)
- Gothenburg University,Göteborgs universitet,Institutionen för medicin, avdelningen för molekylär och klinisk medicin,Institute of Medicine, Department of Molecular and Clinical Medicine
-
- Sartipy, U. (författare)
- Karolinska Institute,Karolinska Institutet,Karolinska Inst, Sweden; Karolinska Univ Hosp, Sweden,Karolinska University Hospital
-
- Tonnessen, T. (författare)
- Oslo Univ Hosp, Norway,Oslo university hospital,University of Oslo
-
- Jeppsson, Anders, 1960 (författare)
- University of Gothenburg,Gothenburg University,Göteborgs universitet,Institutionen för medicin, avdelningen för molekylär och klinisk medicin,Institute of Medicine, Department of Molecular and Clinical Medicine,Univ Gothenburg, Sweden; Sahlgrens Univ Hosp, Sweden,Sahlgrenska University Hospital,Sahlgrenska Academy
-
- Mahn, CJ (författare)
- Univ Gothenburg, Sweden; Sahlgrens Univ Hosp, Sweden
-
visa färre...
-
(creator_code:org_t)
- Elsevier BV, 2023
- 2023
- Engelska.
-
Ingår i: American Heart Journal. - : Elsevier BV. - 0002-8703 .- 1097-6744. ; 259, s. 1-8
- Relaterad länk:
-
https://liu.diva-por... (primary) (Raw object)
-
visa fler...
-
http://dx.doi.org/10... (free)
-
https://gup.ub.gu.se...
-
https://doi.org/10.1...
-
http://kipublication...
-
https://urn.kb.se/re...
-
https://lup.lub.lu.s...
-
visa färre...
Abstract
Ämnesord
Stäng
- The TACSI trial (ClinicalTrials.gov Identifier: NCT03560310) tests the hypothesis that 1-year treatment with dual antiplatelet therapy with acetylsalicylic acid (ASA) and ticagrelor is superior to only ASA after isolated coronary artery bypass grafting (CABG) in patients with acute coronary syndrome. The TACSI trial is an investor-initiated pragmatic, prospective, multinational, multicenter, open-label, registry-based randomized trial with 1:1 randomization to dual antiplatelet therapy with ASA and ticagrelor or ASA only, in patients undergoing first isolated CABG, with a planned enrollment of 2200 patients at Nordic cardiac surgery centers. The primary efficacy end point is a composite of time to all-cause death, myocardial infarction, stroke, or new coronary revascularization within 12 months after randomization. The primary safety end point is time to hospitalization due to major bleeding. Secondary efficacy end points include time to the individual components of the primary end point, cardiovascular death, and rehospitalization due to cardiovascular causes. High-quality health care registries are used to assess primary and secondary end points. The patients will be followed for 10 years. The TACSI trial will give important information useful for guiding the antiplatelet strategy in acute coronary syndrome patients treated with CABG.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Kardiologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cardiac and Cardiovascular Systems (hsv//eng)
Nyckelord
- artery-bypass surgery
- graft failure
- clopidogrel
- ticagrelor
- aspirin
- association
- guidelines
- outcomes
- benefit
- events
- Cardiovascular System & Cardiology
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Malm, Carl Johan
-
Alfredsson, Joak ...
-
Erlinge, David
-
Gudbjartsson, T.
-
Gunn, J.
-
James, S.
-
visa fler...
-
Moller, C. H.
-
Nielsen, Susanne ...
-
Sartipy, U.
-
Tonnessen, T.
-
Jeppsson, Anders ...
-
Mahn, CJ
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Kardiologi
- Artiklar i publikationen
-
American Heart J ...
- Av lärosätet
-
Göteborgs universitet
-
Karolinska Institutet
-
Linköpings universitet
-
Lunds universitet